Atrial fibrillation and vascular disease-a bad combination

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Atrial fibrillation and vascular disease-a bad combination. / Bjerring Olesen, Jonas; Gislason, Gunnar Hilmar; Torp-Pedersen, Christian; Lip, Gregory Y H.

I: Clinical Cardiology, Bind 35 Suppl 1, 2012, s. S15-20.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Bjerring Olesen, J, Gislason, GH, Torp-Pedersen, C & Lip, GYH 2012, 'Atrial fibrillation and vascular disease-a bad combination', Clinical Cardiology, bind 35 Suppl 1, s. S15-20. https://doi.org/10.1002/clc.20955

APA

Bjerring Olesen, J., Gislason, G. H., Torp-Pedersen, C., & Lip, G. Y. H. (2012). Atrial fibrillation and vascular disease-a bad combination. Clinical Cardiology, 35 Suppl 1, S15-20. https://doi.org/10.1002/clc.20955

Vancouver

Bjerring Olesen J, Gislason GH, Torp-Pedersen C, Lip GYH. Atrial fibrillation and vascular disease-a bad combination. Clinical Cardiology. 2012;35 Suppl 1:S15-20. https://doi.org/10.1002/clc.20955

Author

Bjerring Olesen, Jonas ; Gislason, Gunnar Hilmar ; Torp-Pedersen, Christian ; Lip, Gregory Y H. / Atrial fibrillation and vascular disease-a bad combination. I: Clinical Cardiology. 2012 ; Bind 35 Suppl 1. s. S15-20.

Bibtex

@article{e87ca0958ec1460c93d1e74c437845e0,
title = "Atrial fibrillation and vascular disease-a bad combination",
abstract = "This article provides an overview of (i) the risk of stroke associated with vascular disease (acute coronary syndromes and peripheral artery disease) in patients with atrial fibrillation, (ii) the frequent coexistence of vascular disease in patients with atrial fibrillation and, (iii) the cardiovascular risk associated with the coexisting of the two diseases. The literature on this topic is relatively sparse, and we discuss results from both clinical trials and observational studies. There is a clear indication of an increased stroke risk associated with vascular disease in patients with atrial fibrillation. Indeed, patients with atrial fibrillation often had coexisting vascular disease (around 18%), and the combination of the two diseases substantially increases the risk of future cardiovascular events. The increased risk associated with peripheral artery disease in atrial fibrillation is even more pronounced. Patients with atrial fibrillation and stable vascular disease should be treated with oral anticoagulation only, although when these patients present with acute coronary syndrome and/or undergo coronary stenting, concomitant treatment with antiplatelet drugs is indicated. To guide antithrombotic management in patients with atrial fibrillation, several stroke and bleeding risk prediction schemes have been developed. Clin. Cardiol. 2012 DOI: 10.1002/clc.20955 Dr. Olesen received an honorarium through an educational grant from Sanofi Aventis for time and expertise spent writing this article. Dr Lip has served as a consultant for Bayer, Astellas, Merck, AstraZeneca, Sanofi, BMS/Pfizer, Biotronik, Portola and Boehringer Ingelheim and has been on the speakers bureau for Bayer, BMS/Pfizer, Boehringer Ingelheim, and Sanofi-Aventis. Drs. Gislason and Torp-Pedersen disclose no conflicts of interest.",
author = "{Bjerring Olesen}, Jonas and Gislason, {Gunnar Hilmar} and Christian Torp-Pedersen and Lip, {Gregory Y H}",
note = "{\textcopyright} 2012 Wiley Periodicals, Inc.",
year = "2012",
doi = "10.1002/clc.20955",
language = "English",
volume = "35 Suppl 1",
pages = "S15--20",
journal = "Clinical Cardiology",
issn = "0160-9289",
publisher = "Wiley Periodicals, Inc.",

}

RIS

TY - JOUR

T1 - Atrial fibrillation and vascular disease-a bad combination

AU - Bjerring Olesen, Jonas

AU - Gislason, Gunnar Hilmar

AU - Torp-Pedersen, Christian

AU - Lip, Gregory Y H

N1 - © 2012 Wiley Periodicals, Inc.

PY - 2012

Y1 - 2012

N2 - This article provides an overview of (i) the risk of stroke associated with vascular disease (acute coronary syndromes and peripheral artery disease) in patients with atrial fibrillation, (ii) the frequent coexistence of vascular disease in patients with atrial fibrillation and, (iii) the cardiovascular risk associated with the coexisting of the two diseases. The literature on this topic is relatively sparse, and we discuss results from both clinical trials and observational studies. There is a clear indication of an increased stroke risk associated with vascular disease in patients with atrial fibrillation. Indeed, patients with atrial fibrillation often had coexisting vascular disease (around 18%), and the combination of the two diseases substantially increases the risk of future cardiovascular events. The increased risk associated with peripheral artery disease in atrial fibrillation is even more pronounced. Patients with atrial fibrillation and stable vascular disease should be treated with oral anticoagulation only, although when these patients present with acute coronary syndrome and/or undergo coronary stenting, concomitant treatment with antiplatelet drugs is indicated. To guide antithrombotic management in patients with atrial fibrillation, several stroke and bleeding risk prediction schemes have been developed. Clin. Cardiol. 2012 DOI: 10.1002/clc.20955 Dr. Olesen received an honorarium through an educational grant from Sanofi Aventis for time and expertise spent writing this article. Dr Lip has served as a consultant for Bayer, Astellas, Merck, AstraZeneca, Sanofi, BMS/Pfizer, Biotronik, Portola and Boehringer Ingelheim and has been on the speakers bureau for Bayer, BMS/Pfizer, Boehringer Ingelheim, and Sanofi-Aventis. Drs. Gislason and Torp-Pedersen disclose no conflicts of interest.

AB - This article provides an overview of (i) the risk of stroke associated with vascular disease (acute coronary syndromes and peripheral artery disease) in patients with atrial fibrillation, (ii) the frequent coexistence of vascular disease in patients with atrial fibrillation and, (iii) the cardiovascular risk associated with the coexisting of the two diseases. The literature on this topic is relatively sparse, and we discuss results from both clinical trials and observational studies. There is a clear indication of an increased stroke risk associated with vascular disease in patients with atrial fibrillation. Indeed, patients with atrial fibrillation often had coexisting vascular disease (around 18%), and the combination of the two diseases substantially increases the risk of future cardiovascular events. The increased risk associated with peripheral artery disease in atrial fibrillation is even more pronounced. Patients with atrial fibrillation and stable vascular disease should be treated with oral anticoagulation only, although when these patients present with acute coronary syndrome and/or undergo coronary stenting, concomitant treatment with antiplatelet drugs is indicated. To guide antithrombotic management in patients with atrial fibrillation, several stroke and bleeding risk prediction schemes have been developed. Clin. Cardiol. 2012 DOI: 10.1002/clc.20955 Dr. Olesen received an honorarium through an educational grant from Sanofi Aventis for time and expertise spent writing this article. Dr Lip has served as a consultant for Bayer, Astellas, Merck, AstraZeneca, Sanofi, BMS/Pfizer, Biotronik, Portola and Boehringer Ingelheim and has been on the speakers bureau for Bayer, BMS/Pfizer, Boehringer Ingelheim, and Sanofi-Aventis. Drs. Gislason and Torp-Pedersen disclose no conflicts of interest.

U2 - 10.1002/clc.20955

DO - 10.1002/clc.20955

M3 - Journal article

C2 - 22246947

VL - 35 Suppl 1

SP - S15-20

JO - Clinical Cardiology

JF - Clinical Cardiology

SN - 0160-9289

ER -

ID: 40155604